Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$62.0 million.

  • Indivior Pharmaceuticals' Net Cash Flow fell 34285.71% to -$62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.0 million, marking a year-over-year increase of 14438.2%. This contributed to the annual value of $3.0 million for FY2024, which is 10065.36% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Net Cash Flow is -$62.0 million, which was down 34285.71% from $136.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Net Cash Flow registered a high of $136.0 million during Q2 2025, and its lowest value of -$328.0 million during Q4 2023.
  • Over the past 4 years, Indivior Pharmaceuticals' median Net Cash Flow value was -$14.0 million (recorded in 2024), while the average stood at -$34.3 million.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Net Cash Flow crashed by 58333.33% in 2023, and later skyrocketed by 35000.0% in 2024.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Net Cash Flow stood at -$48.0 million in 2022, then plummeted by 583.33% to -$328.0 million in 2023, then skyrocketed by 109.45% to $31.0 million in 2024, then plummeted by 300.0% to -$62.0 million in 2025.
  • Its Net Cash Flow stands at -$62.0 million for Q3 2025, versus $136.0 million for Q2 2025 and $53.0 million for Q1 2025.